Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), the first and only subcutaneously (SC) ...

The complex, built in 2011 to host large-scale events and is recognized as a significant aquatic training facility in ...